RecruitingNCT07553637
ALTO-207 for treatment-resistant depression
About this title
Read the official source — NCT07553637Medication studyAges 18–75United States + United Kingdom
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
What will I do during this study?
Depending on your assigned group, you receive ALTO-207 or a matching placebo (an inactive comparison treatment). The ALTO-207 group takes the study medication twice daily.
- Listed locations
- Dothan and 62 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 20, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 178
- Sponsor
- Alto Neuroscience
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07553637
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Trial of ALTO-207 in Adults With Treatment-resistant Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Dothan, United States · Phoenix, United States · Chino, United States
59 more locations
- La Jolla, United States
- Los Angeles, United States
- Oakland, United States
- Oceanside, United States
- Palo Alto, United States
- Sacramento, United States
- San Diego, United States
- San Jose, United States
- Valley Village, United States
- Wilton, United States
- Saint Augustine, United States
- Albany, United States
- Marietta, United States
- Savannah, United States
- Snellville, United States
- Naperville, United States
- Indianapolis, United States
- Annapolis, United States
- Baltimore, United States
- Pikesville, United States
- Rockville, United States
- Worcester, United States
- Ann Arbor, United States
- Bloomfield Hills, United States
- Grand Rapids, United States
- St Louis, United States
- Toms River, United States
- Amherst, United States
- Cedarhurst, United States
- Lewiston, United States
- Syracuse, United States
- Cary, United States
- Charlotte, United States
- Cincinnati, United States
- Dayton, United States
- Garfield Heights, United States
- East Providence, United States
- North Myrtle Beach, United States
- Austin, United States
- Bryan, United States
- Dallas, United States
- Fort Worth, United States
- Galveston, United States
- Houston, United States
- Irving, United States
- Plano, United States
- Fairfax, United States
- Seattle, United States
- South Charleston, United States
- Antrim, United Kingdom
- Birmingham, United Kingdom
- Bristol, United Kingdom
- Cardiff, United Kingdom
- Exeter, United Kingdom
- London, United Kingdom
- Nottingham, United Kingdom
- Oxford, United Kingdom
- Prescot, United Kingdom
- Sheffield, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Alto Neuroscience.
Does this study involve medication?
Yes. The study involves medication, including ALTO-207 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
